Hepatit B Enfeksiyonunda Karaciğer Histopatolojik Evreleri ile Albumin-Bilirubin Skoru Arasındaki İlişki

Amaç: Bu çalışmada albümin-bilirubin (ALBI) skorunun belirgin karaciğer fibrozisini saptamada duyarlılık ve özgüllüğü araştırıldı ve bu bulgular fibrozis-4 (FIB-4) ve aspartat aminotransferaz/trombosit oranı indeksi (aspartate aminotransferase to platelet ratio index, APRI) skorları ile karşılaştırıldı. Gereç ve Yöntemler: Bu çalışmaya toplam 69 hasta dahil edildi. Hastaların 54’ü (%78,3) erkek ve 15’i (%21,7) kadın idi. Kronik hepatit B virüs (HBV) enfeksiyonu nedeniyle karaciğer biyopsi yapılan hastaların seroloji, moleküler analiz, biyokimyasal parametreler ve patoloji sonuçları retrospektif olarak değerlendirildi. ALBI, APRI ve FIB-4 skorları hesaplandı. Fibrozis evresi F≥2 ve F≥4'ü tahmin etmek için ALBI, APRI ve FIB-4 skorları, alıcı işlem karakteristiği (receiver operator characteristic, ROC) eğrisi analizi kullanılarak araştırıldı. Bulgular: ALBI, APRI ve FIB-4 skorları için F≥2 tahmininde %95 güven aralığı (GA) ile ROC eğrisi altında kalan alan, sırasıyla, 0,613 (%95 GA: 0,463-0,762; p=0,160), 0,658 (%95 GA: 0,513-0,803; p=0.040) ve 0,731(%95 GA: 0,570-0,891; p=0,004) iken F≥4 tahmininde ise sırasıyla, 0,758 (%95 GA: 0,544-0,971; p=0,090), 0,604 (%95 GA: 0,451-0,757; p=0,490) ve 0,923 (%95 GA: 0,856-0,990; p=0,005) idi. ALBI skoru için duyarlılık ve özgüllük değerleri F≥2 tahmininde -2.81 kesim değeri için sırasıyla, %61,1 ve %64,7 iken F≥4 tahmininde -2.78 kesim değeri için sırasıyla, %75,0 ve %70,8 idi. Sonuç: Kronik HBV’li hastalarda F≥2’yi belirlemek için ALBI skoru kullanılabilir. Ancak, bu yaklaşımın F≥4'ü saptamak için diğer invaziv olmayan yöntemlerden üstün olup olmadığı henüz açık değildir.
Anahtar Kelimeler:

Hepatit B, kronik, biyopsi, fibrozis

Relationship between Histopathological Stages of Liver and Albumin-Bilirubin Score in Hepatitis B Infection

Aim: In this study, sensitivity and specificity of the albumin-bilirubin (ALBI) score were investigated to detect significant liver fibrosis, and these findings were then compared to fibrosis-4 (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) scores. Material and Methods: A total of 69 patients were included in the study. Of these patients, 54 (78.3%) were male and 15 (21.7%) were female. Serology, molecular analysis, biochemical parameters, and pathology results of the patients who underwent a liver biopsy due to a chronic hepatitis B virus (HBV) infection, were retrospectively evaluated. ALBI, APRI, and FIB-4 scores were calculated. To predict the fibrosis stage, F≥2 and F≥4, ALBI, APRI, and FIB-4 scores were investigated using the receiver operator characteristic (ROC) curve analysis. Results: The area under the ROC curve with 95% confidence interval (CI) for the ALBI, APRI, and FIB-4 scores were 0.613 (95% CI: 0.463-0.762, p=0.160), 0.658 (95% CI: 0.513-0.803, p=0.040), and 0.731 (95% CI: 0.570-0.891, p=0.004), respectively, to predict the F≥2, and 0.758 (95% CI: 0.544-0.971, p=0.090), 0.604 (95% CI:0.451-0.757, p=0.490), and 0.923 (95% CI: 0.856-0.990, p=0.005), respectively, in prediction of F≥4. The sensitivity and specificity rates of the ALBI score were 61.1% and 64.7%, respectively, for the cut-off value of -2.81 in predicting F≥2, and 75.0% and 70.8% for the cut-off value of -2.78 in predicting F≥4. Conclusion: ALBI scores can be used to detect F≥2 in patients with chronic HBV. However, it is not yet clear whether this approach is superior to other non-invasive methods for detecting F≥4.

___

  • Xia Y, Liang TJ. Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection. Gastroenterology. 2019;156(2):311-24.
  • who.int [Internet]. Hepatitis B. [Cited: 2020 January 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
  • Hyun Kim B, Ray Kim W. Epidemiology of hepatitis B virus infection in the United States. Clin Liver Dis (Hoboken). 2018;12(1):1-4.
  • Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.
  • Özkan H. Epidemiology of chronic hepatitis B in Turkey. Euroasian J Hepatogastroenterol. 2018;8(1):73-4.
  • Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine (Baltimore). 2019;98(18):e15412.
  • Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98.
  • Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52.
  • Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27(6):638-43.
  • Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol. 2011;49(7):871-930. German.
  • Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5(3):40.
  • Ma J, Jiang Y, Gong G. Evaluation of seven non-invasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25(4):428-34.
  • Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39(2):239-44.
  • Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31(8):1873-8.
  • López Panqueva RDP. Useful algorithms for histopathological diagnosis of liver disease based on patterns of liver damage, Rev Col Gastroenterol. 2016;31(4):443-57.
  • Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M, et al. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res. 2019;49(7):731-42.
  • Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14.
  • Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
  • McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265-9.
  • Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
  • Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.
  • Chan AW, Chan RC, Wong GL, Wong VW, Choi PC, Chan HL, et al. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. J Gastroenterol Hepatol. 2015;30(9):1391-6.
  • Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-VenierV, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.
  • Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607.
  • Stauber RE, Lackner C. Non-invasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol. 2007;13(32):4287-94.
  • Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682-94.
  • Bulut C, Yetkin MA, Çaydere M, Erdinç FŞ, Kınıklı S, Tülek N, et al. [Assessment of noninvasive methods for prediction of fibrosis in patients with chronic hepatitis B]. Flora 2007;12(3):128-34. Turkish.
  • Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. J Dig Dis. 2009;10(1):7-14.
  • Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the non-invasive evaluation of liver fibrosis. Ann Hepatol. 2008;7(4):350-7.
  • Saad EA. Non-invasive assessment of liver fibrosis using serum markers. J Pharm Chem Biol Sci. 2014;2(2):59-76.
  • Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new non-invasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep. 2016;6:32875.
  • Dong XQ, Wu Z, Li J, Wang GQ, Zhao H; China HepB-Related Fibrosis Assessment Research Group. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study. J Gastroenterol Hepatol. 2019;34(4):755-63.
  • Serag WM, Mohamed MM, Elsayed BE, Abd-Elhamed SM. Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a non-invasive tool. Turk J Med Sci. 2019;49(4):1145-50.
  • Liu DP, Lu W, Zhang ZQ, Wang YB, Ding RR, Zhou XL, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat. 2018;25(5):581-9.
  • Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142.
  • Alsebaey A, Badr R, Abdelsameea E, Amer MO, Eljaky MA, El-Azab G, et al. King’s fibrosis, fibrosis index, GPR, and ALBI score are useful models for liver fibrosis in chronic hepatitis B patients pre- and post-treatment. Hepat Mon. 2019;19(11):e96081.
Düzce Tıp Fakültesi Dergisi-Cover
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1999
  • Yayıncı: Düzce Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Hipertansif Gebeliklerde Farklı Cut-off Düzeyleri Kullanılarak Anormal Proteinüri Saptanmasında Spot İdrar Protein Ölçümünün Rolü

Taha TAKMAZ, Irana GORCHİYEVA, Belfin Nur ARİCİ HALİCİ, Ali TOPRAK, Caglar CETİN, Mehmet Serdar KUTUK

Nazal Septum Deviasyonunun Göz Muayenesi Bulgularına Etkileri: Nazal Septum Deviasyonu Görme Bozukluğuna Sebep Olur mu?

Fatih Alper AKCAN, Kuddusi TEBERİK, Abdullah BELADA, İlhan ÜNLÜ, Yusuf DÜNDAR

Pediatrik Ailevi Akdeniz Ateşinde Basit Hemogram İndeksleri ile Hastalık Şiddet Skorları Arasındaki İlişkinin Değerlendirilmesi

Vildan GÜNGÖRER, Şükrü  ARSLAN

Türk Popülasyonunda Bilgisayarlı Tomografide COVID-19 Hastalarının Trakeobronşiyal Açılarının Ölçümü ve Pnömoni Şiddeti ile Korelasyonu

Burcu AKMAN, Hatice Ayça ATA KORKMAZ

Tıbbi Araştırmalarda Biyoistatistiksel Yöntemlerin Bilinçli ve Doğru Kullanımı: Planlamadan Sonuçların Raporlanmasına - Bölüm I

Erdem KARABULUT

Vücut Kitle İndeksinin Trombosit Aferez Donörlerinin Trombosit Sayıları ve Donasyon Sıklığı ile İlişkisi

Sevil SADRİ, Hülya BİLGEN

Tip 2 Diyabetli Bireylerde Aterojenik Plazma İndeksi ile İlişkili Visseral Adipozite İndekslerinin Değerlendirilmesi

Sevil KARAHAN YILMAZ, Fatih ÖZÇİÇEK, Cuma MERTOĞLU, Yusuf Kemal ARSLAN

Küresel Pandemi COVID-19’un Bir Sonucu Olarak Ukrayna ve Güney Afrika'da Tıp Bilimi Disiplinlerinin Uzaktan Eğitim Deneyimi

Olga AVİLOVA, Victoria EROKHİNA, Kentse MPOLOKENG, Jeshika LUCKRAJH, Oleh VOVK, Oleksandr STEPANENKO, Uyen NGUYEN DO TO

Viral Siğili Olan Hastalarda Kontrol Grubuna Kıyasla Daha Düşük Vitamin B12 Seviyeleri: Retrospektif Bir Çalışma

Gökşen ERTUĞRUL, Habibullah AKTAŞ

Kırım-Kongo Kanamalı Ateşinde Serum Alfa Defensin-1 Düzeylerinin Klinik Seyir ve Prognoz ile İlişkisi

Meral BAYAR, Emine PARLAK, Esra LALOĞLU, Mehmet PARLAK, Sinan YILMAZ